Created at	Source	Raw Value	Validated value
Dec. 2, 2022, 4 p.m.	usa	Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the safety and tolerability of efgartigimod in patients with post-COVID-19 POTS	Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the efficacy of efgartigimod in reducing the severity of post-COVID-19 POTS symptoms;Evaluate the safety and tolerability of efgartigimod in patients with post-COVID-19 POTS